Bloomberg Businessweek The Next Biotech Breakthrough
Feb 5, 2026
Jenny Rooke, founder and managing director of Genoa Ventures with nearly two decades in biotech investing. She discusses takeaways from the JPMorgan conference and the upbeat mood around AI in health. Conversation covers early-stage funding shifts, how AI speeds discovery yet leaves long development timelines, and why investor patience matters for precision medicine.
AI Snips
Chapters
Transcript
Episode notes
Conference Mood Shift
- The JP Morgan biotech conference felt "cautiously optimistic" this year with more attendees and energy than last year.
- Jenny Rooke links that optimism to AI's real impacts on health and science and improved funding dynamics.
Resilience Fuels Biotech Progress
- Despite recent funding uncertainties, resilience among driven researchers and entrepreneurs sustains biotech innovation.
- Jenny Rooke notes grit and adaptability are creating new funding and commercialization paths.
AI Speeds Scientific Iteration
- AI accelerates the scientific "flywheel" by enabling faster data cycles and iteration for researchers and entrepreneurs.
- That acceleration increases opportunities for new ventures and novel research paths according to Jenny Rooke.